MEK inhibitor breakthroughs in Noonan syndrome — the targeted MAPK pathway therapies demonstrating cardiac function improvement in children with severe hypertrophic cardiomyopathy, alongside Novo Nordisk's February 2026 FDA approval of once-weekly Sogroya (somapacitan) for Noonan-associated growth failure — represent the most transformative therapeutic innovations in this...

RAS-MAPK pathway inhibition in Noonan syndrome — the emerging targeted therapy approach addressing the underlying molecular pathophysiology of PTPN11, SOS1, RAF1, and KRAS mutations, representing the most scientifically transformative development in the Noonan Syndrome Market — creates the most clinically anticipated market segment, with MEK inhibitors and SHP2 inhibitors reflecting...